Nucleic acid ligands to the prostate specific membrane antigen
AssigneeGilead Sciences, Inc.
InventorsShawn E. Lupold, Yun Lin, Brian J. Hicke, Donald S. Coffey
Life of this patent
Estimating the term…
Abstract
Methods are provided for generating nucleic acid ligands of Prostate Specific Membrane Antigen (PSMA). The methods of the invention use the SELEX method for the isolation of nucleic acid ligands. The invention also includes nucleic acid ligands to PSMA, and methods and compositions for the treatment and diagnosis of disease using the nucleic acid ligands.
Claims15
A nucleic acid ligand to Prostate Specific Membrane Antigen (PSMA) identified according to a method comprising:
- a) preparing a candidate mixture of nucleic acids;
- b) contacting the candidate mixture of nucleic acids with PSMA, wherein nucleic acids having an increased affinity to PSMA relative to the candidate mixture may be partitioned from the remainder of the candidate mixture;
- c) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture;
- and
- d) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for nucleic acids with relatively higher affinity and specificity for binding to PSMA, whereby a nucleic acid ligand of PSMA may be identified.
A purified and isolated non-naturally occurring nucleic acid ligand to PSMA.
A purified and non-naturally occurring RNA ligand to PSMA wherein said ligand is selected from the group consisting of SEQ ID NOS:3-27.
A method for the identifying nucleic acid ligands to PSMA, comprising:
- a) preparing a candidate mixture of nucleic acids;
- b) contacting the candidate mixture of nucleic acids with PSMA, wherein nucleic acids having an increased affinity to PSMA relative to the candidate mixture may be partitioned from the remainder of the candidate mixture;
- c) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture;
- and
- d) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for nucleic acids with relatively higher affinity and specificity for binding to PSMA, whereby a nucleic acid ligand of PSMA may be identified.
Dependencies are inferred from the claim text.